Stock listing

NASDAQ:CYCN Cyclerion Therapeutics, Inc. Stock

Home listing (NASDAQ) of Cyclerion Therapeutics, Inc.

Follow Cyclerion Therapeutics, Inc. into a list and get an email when it puts out news.

Cyclerion Therapeutics, Inc. logo
Ticker
NASDAQ:CYCN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Cyclerion Therapeutics, Inc. news

Cyclerion Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 47 in all · newest Apr 1, 2026 · oldest 2019
Decks
22 decks · latest July 2026

Where Cyclerion Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CYCN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CYCNBOATSUnited StatesUSD

Valuation

Statements: Year to Dec 31, 2025 · balance Sep 30, 2026

Enterprise value
No market cap
P/E
No market cap
EV/sales
No market cap
EV/EBITDA
No market cap
Price/book
No market cap
Gross margin
100.0%
Operating margin
−239.8%
Net margin
−170.1%
Debt to equity
0.0×
Beta vs S&P 500
0.49

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
56.00 USD · Analysts' mean
EPS, year to Dec 2026
-8.40 · 1 analyst

Team and board

Officers

OfficerRole
Jonathan ViolinChief Executive Officer
Mark VignolaChief Financial Officer
Eva StroynowskiVP, Investor Relations
Angela SheVP, R&D Strategy and Operations
Joshua ParkVP, Protein Sciences
Kyle BreidenstineSVP, Finance
Maribel ReyesVP, Clinical Pharmacology and Translational Science
Michael OldhamVP, Clinical Development
Robin WojcieszekSVP, Regulatory, Drug Safety and Medical Writing
Vanessa TeachoutVP, Head of Clinical Operations
Gan WeiChief Technology Officer
Matthew LeoniChief Medical Officer

Board

DirectorRole
Tomas KiselakChairman
Andrew GottesdienerDirector
Heidi HensonDirector
Jonathan ViolinChief Executive Officer
Michelle PerniceDirector
Nimish ShahDirector

Events

QuarterResultsShare move
Q2 2026Aug 4, 2026+1.7%
Q4 2025Mar 31, 2026 · Before open+7.3%
Q3 2025Nov 12, 2025−10.6%
Q2 2025Aug 5, 2025−14.2%
Q1 2025May 5, 2025 · After close+1.3%
Q4 2024Mar 3, 2025 · After close+9.6%
Q3 2024Nov 11, 2024 · After close−23.4%
Q2 2024Aug 7, 2024 · Before open−1.1%
Q1 2024May 7, 2024 · After close+1.0%
Q4 2023Mar 5, 2024 · After close−3.4%
All 20 quarters
QuarterResultsShare move
Q3 2023Nov 13, 2023 · After close−9.1%
Q2 2023Jul 28, 2023 · After close+14.2%
Q1 2023May 12, 2023 · Before open−25.1%
Q4 2022Mar 22, 2023 · After close−11.6%
Q3 2022Nov 3, 2022 · After close−20.5%
Q2 2022Aug 9, 2022 · After close+1.0%
Q1 2022May 4, 2022 · After close−5.3%
Q4 2021Feb 24, 2022 · After close−3.5%
Quarter to Sep 30, 2021Nov 9, 2021 · After close−5.4%
Quarter to Jun 30, 2021Jul 29, 2021 · After close−0.7%

Open Events

Decks

DeckKindSlidesDate
Korsana Biosciences — Merger or Acquisition (July 2026)Merger or acquisition32 slidesJuly 2026
Merger or Acquisition (April 2026)Merger or acquisition52 slidesApr 1, 2026
Merger or Acquisition (April 2026)Merger or acquisition56 slidesApr 1, 2026
Korsana Biosciences — Merger or Acquisition (April 2026)Merger or acquisition31 slidesApril 2026
Investor Presentation (February 2026)Investor deck22 slidesFeb 17, 2026
Korsana Biosciences — Investor Presentation (February 2026)Investor deck28 slidesFebruary 2026
Investor Presentation (January 2026)Investor deck28 slidesJan 6, 2026
Investor Presentation (January 2026)Investor deck23 slidesJanuary 2026
Investor Presentation (January 2026)Investor deck22 slidesJanuary 2026
Corporate Update (September 2025)Corporate update15 slidesSep 23, 2025
All 22 decks
DeckKindSlidesDate
Technical Presentation (July 2022)Technical30 slidesJul 28, 2022
Investor Presentation (June 2022)Investor deck63 slidesJun 10, 2022
Investor Presentation (September 2021)Investor deck59 slidesSep 30, 2021
Investor Presentation (April 2021)Investor deck59 slidesApr 27, 2021
Corporate Update (January 2021)Corporate update37 slidesJan 13, 2021
Corporate Update (October 2020)Corporate update24 slidesOct 14, 2020
Investor Presentation (July 2020)Investor deck37 slidesJul 9, 2020
Corporate Update (July 2020)Corporate update35 slidesJul 9, 2020
UMDF Power Surge 2020Conference7 slidesJun 26, 2020
Corporate Update (April 2020)Corporate update35 slidesApr 14, 2020
J.P. Morgan Healthcare Conference 2020Conference16 slidesJan 13, 2020
Corporate Update (October 2019)Corporate update17 slidesOct 30, 2019

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue2.07M2.00M0297.0K3.32M2.30M4.51M000
Cost of revenue1.31M5.58M472.0K56.4M95.1M1.53M1.75M2.17M
Gross profit2.07M2.00M-1.31M-5.28M3.32M-54.1M-90.6M-1.53M-1.75M-2.17M
Research and development959.0K286.0K1.51M5.98M37.6M56.4M95.1M87.7M78.8M50.9M
Selling, general and administrative6.09M5.34M8.13M12.9M20.6M28.8M34.4M27.5M15.1M12.7M
Operating income-4.97M-3.63M-13.0M-18.5M-55.2M-81.3M-125.0M-115.3M-93.9M-63.6M
Depreciation and amortization65.0K65.0K472.0K2.30M2.70M1.53M1.75M2.17M
EBITDA-12.9M-18.5M-54.7M-79.0M-122.3M-113.7M-92.2M-61.4M
Interest expense294.0K16.0K588.0K0000
Income before tax-3.53M-3.06M-12.6M-18.2M-51.6M-77.8M-123.0M-115.3M-93.9M-63.6M
Income tax8.42M-294.0K16.0K-5.13M-2.03M1.37M00
Net income-3.53M-3.06M-5.26M-44.1M-51.6M-77.8M-123.0M-115.3M-93.9M-63.6M
Earnings per share, basic-7.66-8.50-15.76-141.99-184.72-358.26-628.97-590.94-481.58-324.71

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.24M3.23M7.57M13.4M54.0M54.4M97.6M000
Short-term investments000
Receivables1.00M556.0K096.0K100.0K127.0K1.47M
Inventory805.0K928.0K816.0K1.97M000
Current assets4.63M4.22M8.02M14.8M55.5M58.5M101.2M879.0K1.26M275.0K
Property, plant and equipment1.22M1.47M6.87M79.8M6.50M4.13M3.60M
Goodwill000
Total assets9.98M9.57M13.4M18.1M59.3M115.4M186.5M7.40M5.47M3.88M
Accounts payable508.0K390.0K1.20M2.97M1.83M1.15M3.31M2.78M1.80M1.41M
Current liabilities900.0K725.0K2.09M7.63M11.1M17.0M18.2M17.8M14.0M10.6M
Long-term debt000
Total debt45.7M73.9M
Total liabilities900.0K725.0K2.09M7.63M11.1M55.9M88.7M17.8M14.0M10.6M
Shareholders' equity9.09M8.85M11.3M10.5M48.2M59.5M97.7M-10.4M-8.57M-6.76M
Shares outstanding460.7K359.7K334.0K310.4K279.6K217.2K195.6K195.0K195.0K195.7K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-3.31M-4.33M-21.2M-40.6M-36.5M-72.5M-102.2M-97.5M-81.2M-49.9M
Capital spending0000-7.00K-1.52M-6.89M-3.44M-1.40M-1.45M
Free cash flow-3.31M-4.33M-21.2M-40.6M-36.5M-74.0M-109.1M-100.9M-82.6M-51.3M
Cash from investing10.4M1.46M18.0K-6.71M-3.44M-1.40M-1.45M
Cash from financing3.32M05.02M29.0K30.8M28.1M211.6M100.9M82.6M51.3M
Dividends paid000
Share buybacks-130.0K024.6M165.1M000
Change in cash8.00K-4.34M-5.81M-40.6M-4.27M-44.4M102.6M102.6M102.6M102.6M

Open Financials

Cap table

Built by 6ix from Cyclerion Therapeutics, Inc.’s releases

Common shares
668,764
Fully diluted
668,764

Fully diluted

LineShares
Common shares668,764

Share count over time

CountShares
Nov 22, 2026668,764
Aug 26, 2026

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Fidelity Growth Company Fund218K32.6%US$688KNewMay 31, 2026
Fidelity Growth Company K6 Fund60,4089.0%US$190KNewMay 31, 2026
Fidelity Series Growth Company Fund57,3008.6%US$180KNewMay 31, 2026
Vanguard Extended Market Index Fund30,9154.6%US$105K+14,778Jun 30, 2026
Fidelity Extended Market Index Fund24,7303.7%US$77,900+2,315May 31, 2026
Fidelity Nasdaq Composite Index ETF21,2003.2%US$66,780+370May 31, 2026
Fidelity Small Cap Growth Fund9,9001.5%US$34,056No changeJul 31, 2026
Fidelity Small Cap Growth K6 Fund4,9820.74%US$17,138No changeJul 31, 2026
Fidelity Series Total Market Index Fund3,3670.50%US$10,606No changeMay 31, 2026
Dimensional US Sustainability Core 1 ETF3,3180.50%US$11,414NewJul 31, 2026
All 16 holders
HolderSharesOf the companyValueChangeAs of
Select Health Care Portfolio3,0000.45%US$9,450NewMay 31, 2026
Fidelity Total Market Index Fund2,2600.34%US$7,119No changeMay 31, 2026
Dimensional U.S. Core Equity 2 ETF2,1890.33%US$7,530NewJul 31, 2026
VIP Health Care Portfolio1,7000.25%US$5,763NewJun 30, 2026
Fidelity Advisor Health Care Fund1,5000.22%US$5,160No changeJul 31, 2026
Dimensional US Core Equity 1 ETF7480.11%US$2,573NewJul 31, 2026

Big stakes

HolderStakeSharesDate
Peter M. Hecht19.40%910KJul 16, 2026
FMR LLC15.00%650KApr 30, 2026
Balyasny Asset Management L.P.7.33%318KJun 30, 2026
ADAR1 Capital Management, LLC7.00%299KJun 30, 2026
J. Wood Capital Advisors LLC5.40%182KMar 25, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Terrance McGuire
Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past)
Director · Apr 1, 2019 – Nov 30, 2023 · Past
Tomas Kiselak
Other companies: Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Viridian Therapeutics, Inc. (Director · Since at least Oct 27, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Sep 27, 2024 · Past)
Chairman · Since at least Apr 1, 2026
Amy Schulman
Other companies: Elevance Health, Inc. (Director · Since at least Dec 10, 2025); Fractyl Health, Inc. (Director · Since at least Feb 1, 2024); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jun 20, 2018); Hudson Executive Investment Corp II (Director · Jan 25, 2021 – Apr 13, 2021 · Past); Ironwood Pharmaceuticals, Inc. (Director · May 31, 2018 – Apr 1, 2019 · Past); Blue Buffalo Pet Products Inc (Director · Apr 24, 2018 – Apr 24, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past)
Director · Apr 1, 2019 – Jun 16, 2020 · Past
Marsha Fanucci
Other companies: Generate Biomedicines, Inc. (Director · Since at least Feb 26, 2026); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Oct 14, 2022 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 5, 2024 · Past); Alnylam Pharmaceuticals, Inc. (Director · Dec 8, 2010 – May 18, 2023 · Past); Ironwood Pharmaceuticals, Inc. (Director · Feb 2, 2010 – Apr 1, 2019 · Past); Momenta Pharmaceuticals Inc (Director · Jun 15, 2006 – Jun 23, 2016 · Past); Millennium Pharmaceuticals Inc (SVP, Chief Financial Officer · Sep 15, 2005 – May 14, 2008 · Past)
Director · Mar 14, 2019 – Jun 14, 2022 · Past
Errol B Desouza
Other companies: Alector, Inc. (Director · Since at least Mar 19, 2024); Royalty Pharma plc (Director · Jun 15, 2020 – May 13, 2025 · Past); Albireo Pharma Inc (CEO, Director · Mar 29, 2010 – Sep 30, 2015 · Past); Palatin Technologies, Inc. (Director · Jul 1, 2006 – Jul 21, 2010 · Past); Gyre Therapeutics, Inc. (Director · Apr 11, 2006 – Oct 1, 2021 · Past); IDEXX Laboratories, Inc. (Director · Jan 30, 2006 – Apr 30, 2009 · Past)
Director · Apr 21, 2021 – Nov 30, 2023 · Past
Gina Consylman
Other companies: Assembly Biosciences, Inc. (Director · Since at least Oct 19, 2020); Bluebird bio Inc (Chief Financial Officer · Nov 4, 2021 – Feb 1, 2022 · Past); Verastem, Inc. (Director · Oct 17, 2018 – Jun 28, 2021 · Past); Ironwood Pharmaceuticals, Inc. (SVP, CFO & Treasurer · Jun 23, 2014 – Mar 26, 2021 · Past); Analogic Corporation (VP-Controller · Mar 1, 2013 – Jun 11, 2014 · Past)
SECRETARY AND TREASURER, Director · Mar 14, 2019 – Mar 14, 2019 · Past
Jonathan Violin
Other companies: Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Dianthus Therapeutics, Inc. (Director · Since at least Sep 11, 2023); Astria Therapeutics Inc (Director · Since at least Jan 28, 2021); Viridian Therapeutics, Inc. (Chief Executive Officer, Director · Oct 27, 2020 – Feb 2, 2023 · Past); Trevena, Inc. (SVP-Scientific Affairs & IR · Jan 29, 2018 – Feb 28, 2018 · Past)
Chief Executive Officer · Since at least Apr 1, 2026
Michael J. Higgins
Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Voyager Therapeutics, Inc. (Chair · Since at least Nov 10, 2015); Pulmatrix, Inc. (Chairman of the PULMATRiX Board of Directors · Since at least Jun 15, 2015); Ironwood Pharmaceuticals, Inc. (Chief Operating Officer · Feb 2, 2010 – Dec 23, 2014 · Past)
Director · Nov 30, 2023 – Mar 25, 2025 · Past
Christopher Wright
Other companies: Wave Life Sciences Ltd. (Chief Medical Officer · Since at least May 28, 2025); Alkermes plc (Director · Since at least May 24, 2022)
Chief Medical Officer · Feb 25, 2021 – Feb 25, 2021 · Past
George H Conrades
Other companies: Oracle Corporation (Director · Since at least May 31, 2018); Akamai Technologies, Inc. (Director · Dec 31, 2017 – May 20, 2018 · Past)
Director · Apr 1, 2019 – Jun 14, 2022 · Past
All 39 people
PersonSeat
Nimish Shah
Other companies: Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Instil Bio, Inc. (Director · Mar 18, 2021 – Mar 23, 2021 · Past)
Director · Since at least Apr 1, 2026
William Huyett
Other companies: Rockley Photonics Holdings Ltd (Director · Aug 11, 2021 – May 17, 2022 · Past); Ironwood Pharmaceuticals, Inc. (Chief Operating Officer · Dec 15, 2017 – Apr 1, 2019 · Past)
Chief Financial Officer · Mar 14, 2019 – Nov 6, 2020 · Past
Andreas Busch
Other companies: Absci Corporation (Chief Innovation Officer · Since at least Mar 17, 2022)
Chief Scientific Officer · Apr 29, 2019 – Jan 20, 2022 · Past
Andrew Gottesdiener
Other companies: Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023)
Director · Since at least Apr 1, 2026
Cheryl Gault
Other companies: Rapport Therapeutics, Inc. (Chief Operating Officer · Since at least Jun 6, 2024)
Chief Operating Officer · Jan 1, 2021 – Jan 20, 2022 · Past
Mark G Currie
Other companies: Ironwood Pharmaceuticals, Inc. (Director · Since at least Jan 4, 2016)
President and CSO · Apr 1, 2019 – Dec 28, 2020 · Past
Michael Mendelsohn
Other companies: Foghorn Therapeutics Inc. (Founder, Board Director, & Chief Strategy Officer, Cardurion Pharmaceuticals · Since at least Oct 22, 2020)
Director · Apr 1, 2019 – Jun 14, 2022 · Past
Peter M Hecht
Other companies: Ironwood Pharmaceuticals, Inc. (Chief Executive Officer, Director · Feb 2, 2010 – Apr 1, 2019 · Past)
Director · Since at least Apr 1, 2019
Rhonda M Chicko
Other companies: Scholar Rock Holding Corporation (Chief Financial Officer · May 23, 2018 – Jan 31, 2019 · Past)
Chief Financial Officer · Since at least Mar 4, 2024
Stephanie Lovell
Other companies: TransMedics Group, Inc. (Director · Since at least Mar 22, 2021)
Director · Apr 1, 2019 – Jun 14, 2022 · Past
Steven Hyman
Other companies: Voyager Therapeutics, Inc. (Director · Since at least Nov 10, 2015)
Director · Jul 25, 2022 – Nov 30, 2023 · Past
Angela SheVP, R&D Strategy and Operations · Since at least Nov 4, 2026
Anjeza GjinoChief Financial Officer · Jan 1, 2021 – Jan 20, 2022 · Past
Dina KatabiDirector · Nov 30, 2023 – Nov 30, 2023 · Past
Eva StroynowskiVP, Investor Relations · Since at least Nov 4, 2026
Gan WeiChief Technology Officer · Since at least Nov 4, 2026
Heidi HensonDirector · Since at least Nov 5, 2026
Joshua ParkVP, Protein Sciences · Since at least Nov 4, 2026
Kevin ChurchwellDirector · Apr 1, 2019 – Jun 24, 2021 · Past
Kyle BreidenstineSVP, Finance · Since at least Nov 4, 2026
Maribel ReyesVP, Clinical Pharmacology and Translational Science · Since at least Nov 4, 2026
Mark VignolaChief Financial Officer · Since at least Nov 4, 2026
Matthew LeoniChief Medical Officer · Since at least Nov 4, 2026
Michael OldhamVP, Clinical Development · Since at least Nov 4, 2026
Michelle PerniceDirector · Since at least Apr 1, 2026
Ole IsacsonDirector · Apr 1, 2019 – Jun 14, 2022 · Past
Regina Margaret GraulSee Remarks, Director · Since at least Dec 1, 2023
Robin WojcieszekSVP, Regulatory, Drug Safety and Medical Writing · Since at least Nov 4, 2026
Vanessa TeachoutVP, Head of Clinical Operations · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Cyclerion Therapeutics, Inc.